Our findings suggest that tirzepatide, through its dual GIP/GLP-1 action, may be superior as a non-IOPlowering adjunct or even as a primary preventive agent in glaucoma management among patients with diabetes, the researchers wrote in their paper
(JAMA, 2023) analyzed insurance claims and found GLP-1 agonist use was associated with a 3.67x increased odds of developing gastroparesis symptoms
This is especially common in people who use insulin or certain diabetes medications, but it can also occur in those without diabetes, particularly if they skip meals or engage in intense exercise without eating enough
4.3.1 Targeting Gln in combination with radiotherapy and chemotherapy Despite the remarkable clinical success of chemoradiotherapy and immunotherapy, many patients still do not benefit from these treatments
[DOI] [PMC free article] [PubMed] [Google Scholar] 11.Gupta A., Madhavan M.V., Sehgal K., Nair N., Mahajan S., Sehrawat T.S., et al
Dezember 2025 07:48 Bewertung mit 5 von 5 Sternen Bringt mich gut durch den Winter